DR. Reddy S Laboratories

NSE: DRREDDY · Pharmaceuticals · sector

₹1,310.90NSE close 2026-10-26

Key numbers

Market cap₹1,09,460 cr

Price₹1,310.90

52w high / low₹1,415 / ₹1,101

P/E33.9xSector median 27.9x

P/B2.9xSector median 2.9x

Book value₹453.8

Dividend yield0.61%Sector median 0.48%

ROE9.0%Sector median 11.7%

ROCE10.1%Sector median 12.3%

OPM15.5%Sector median 14.0%

Debt / equity0.17xSector median 0.16x

EV/EBITDA21.1xSector median 18.6x

Interest cover10.7x

Current ratio1.80x

Sales growth 3y+11.0%Sector median +9.6%

Profit growth 3y-2.4%Sector median +13.3%

PEG–

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹7,172 cr vs borrowings ₹6,294 cr (FY26): cash is higher (net cash).
Borrowings rose in each of the last 3 years (₹1,347 cr → ₹6,294 cr).
Operating profit covered interest 10.7x in the last 12 months.
No promoter shares are pledged.
Operating cash flow was below net profit in 2 of the last 5 years (FY25, FY24).
Revenue was higher than a year earlier in 2 of the last 4 quarters.
Other income was 44% of net profit in the last 12 months.
Dividend paid in 5 of the last 5 financial years.
Price ₹1,310.90 on 2026-10-26: -7.4% from the 52-week high, +19.1% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹1,389.45 · low ₹1,094.05

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	8,038	8,381	8,528	8,572	8,828	8,753	7,546	8,100
EBITDA	2,076	2,273	1,998	2,174	2,010	1,888	382	860
OPM %	25.8%	27.1%	23.4%	25.4%	22.8%	21.6%	5.1%	10.6%
Other income	308	150	522	290	324	269	475	355
Net profit	1,256	1,414	1,593	1,418	1,347	1,210	221	444
EPS (₹)	3.02	16.97	19.12	17.04	16.18	14.53	2.65	5.33
Revenue YoY					+9.8%	+4.4%	-11.5%	-5.5%
Profit YoY					+7.3%	-14.4%	-86.1%	-68.7%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	21,545	24,670	28,011	32,644	33,700	33,228
EBITDA	3,768	6,349	7,933	8,547	6,454	5,140
Net profit	2,182	4,507	5,578	5,655	4,196	3,222
EPS (₹)	26.31	54.29	67.04	67.89	50.41	38.69
Revenue growth		+14.5%	+13.5%	+16.5%	+3.2%	-0.9%
Profit growth		+106.5%	+23.8%	+1.4%	-25.8%	-43.3%
Dividend / share (₹)	25.00	30.00	40.00	40.00	8.00

Compounded growth	3 years	5 years	Last 12 months
Sales	+11.0%	+12.1%	-0.9%
Net profit	-2.4%	+16.5%	-43.3%
EPS	-2.4%	+16.5%	–
Share price	–	-3.6% (2y)	-3.4%

Balance sheet

₹ cr	FY22	FY23	FY24	FY25	FY26
Shareholders' equity	–	23,286	28,255	33,550	37,892
Borrowings	–	1,347	1,652	4,184	6,294
Cash & equivalents	–	6,180	6,133	5,791	7,172
Total assets	–	32,285	38,864	49,427	58,123
Fixed assets	–	5,654	6,249	7,298	10,078
Capital work in progress	–	975	1,351	2,399	1,460
Investments	–	66	106	239	894
Receivables	–	7,248	8,030	9,042	10,123
Inventory	–	4,867	6,355	7,108	7,653
Payables	–	2,268	2,614	2,648	3,038

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	2,811	5,887	4,543	4,643	5,674
Cash from investing	-2,639	-4,137	-4,028	-5,102	-6,549
Cash from financing	-242	-2,686	-376	1,186	829
Capex	1,905	1,886	2,744	3,440	3,840
Free cash flow	906	4,001	1,800	1,203	1,833

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY22	FY23	FY24	FY25	FY26
ROE %	–	19.4%	19.7%	16.9%	11.1%
ROCE %	–	25.0%	24.6%	21.0%	13.0%
Debtor days	–	107	105	101	110
Inventory days	–	232	283	260	228
Payable days	–	108	116	97	91
Cash conversion cycle (days)	–	231	272	264	247
Working capital days	–	179	198	134	145

Shareholding

Holder	% (2026-09-30)
Promoters	26.63%
FIIs	31.39%
DIIs	31.88%
of which Mutual funds	14.14%
of which Insurance	14.59%
Public (non-institutions)	9.90%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	26.64%	26.64%	26.64%	26.64%	26.64%	26.63%	26.64%	26.63%

Promoter group	%
GVP Family Trust	11.51%
VSD Family Trust	9.06%
Kallam Satish Reddy HUF	3.31%
Gunupati Venkateswara Prasad HUF	1.52%
Satish Reddy Kallam	1.21%
Anuradha Gunupati	0.01%
Sharathchandra Reddy Gunupati	0.00%
Gunupati Venkateswara Prasad	0.00%
Deepti Reddy Kallam	0.00%
G Vani Sanjana Reddy	0.00%
Gunupati Mallika Reddy	0.00%
Shravya Reddy Kallam	0.00%
Kallam Vishal Reddy	0.00%
Parvathi Gunupati	0.00%
Shyamala Gunupati	0.00%

Public holders above 1%	%
Life Insurance Corporation of India P & GS Fund	12.14%
J P Morgan Chase Bank NA	11.10%
Isif Equity Ex-top 100 Long-short Fund	5.76%
NPS Trust-a/c SBI Pension Fund Scheme TAX Saver-tier 2	2.93%
Nippon Life India Trustee Ltd-a/c-nippon India Nifty 50 Value 20 Index Fund	1.58%
Parag Parikh Flexi CAP Fund	1.46%
SBI Nifty Index Fund	1.21%

4,76,681 shareholders. Pledged: 0.00% of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
LUPIN	₹89,616 cr	16.2x	4.0x	27.9%	27.9%	30.0%	+18.9%	0.61%

All 185 companies in Pharmaceuticals →

Business segments (FY26)

Segment	Revenue	Share	EBIT	Margin
a) Global Generics	₹29,946 cr	87.0%	₹16,970 cr	56.7%
b) Pharmaceutical Services and Active Ingredients	₹4,267 cr	12.4%	₹600 cr	14.1%
c) Others	₹214 cr	0.6%	₹158 cr	73.9%

Dividends & corporate actions

Ex-date	Action	Detail
2026-07-10	Dividend	Dividend - Rs 8 Per Share
2025-07-10	Dividend	Dividend - Rs 8 Per Share
2024-10-28	Split	Face Value Split (Sub-Division) - From Rs 5/- Per Share To Re 1/- Per Share
2024-07-16	Dividend	Annual General Meeting/Dividend - Rs 40 Per Share
2023-07-11	Dividend	Annual General Meeting/Dividend - Rs 40 Per Share
2022-07-11	Dividend	Annual General Meeting/Dividend - Rs 30 Per Share
2021-07-09	Dividend	Annual General Meeting/Dividend - Rs 25 Per Share
2020-07-13	Dividend	Annual General Meeting/Dividend - Rs 25 Per Share
2019-07-15	Dividend	Annual General Meeting/Dividend - Rs 20 Per Share
2018-07-16	Dividend	Annual General Meeting/Dividend- Rs 20 Per Share
2017-07-17	Dividend	Annual General Meeting/Dividend - Rs 20/- Per Share
2016-07-18	Dividend	Annual General Meeting/ Dividend - Rs 20/- Per Share
2015-07-10	Dividend	Annual General Meeting/Dividend Rs 20/- Per Share
2014-07-11	Dividend	Annual General Meeting / Final Dividend - Rs 18/- Per Share
2013-07-12	Dividend	Annual General Meeting And Dividend Rs.15/- Per Share
2012-06-28	Dividend	Annual General Meeting And Dividend - Rs.13.75 Per Share
2011-06-30	Dividend	Annual General Meeting And Dividend Rs.11.25 Per Share
2011-03-17	Bonus	Scheme Of Arrangement - Bonus Debentures 6:1
2010-07-02	Dividend	Annual General Meeting And Final Dividend Rs.11.25 Per Share
2009-07-03	Other	Agm/Div-Rs.6.25 Per Share

Documents

Links go to the original files on the exchange website.

About the company

Pharmaceuticals: Development, manufacturing & sale of pharmaceutical products, and services


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	DRREDDY
BSE code	500124
ISIN	INE089A01031
Face value	₹1.0
Incorporated	1984-02-24
Website	www.drreddys.com
Plants (India / abroad)	27 / 6

From the company's filings (BRSR FY26).

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.